ALDOMET Drug Patent Profile

Which patents cover Aldomet, and when can generic versions of Aldomet launch?

Aldomet is a drug marketed by Merck and is included in three NDAs.

The generic ingredient in ALDOMET is methyldopa. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyldopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aldomet

A generic version of ALDOMET was approved as methyldopa by RISING on April 18^th, 1985.

Summary for ALDOMET

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	8
Patent Applications:	5,721
DailyMed Link:	ALDOMET at DailyMed

Recent Clinical Trials for ALDOMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Maastricht University Medical Center	Phase 4
University of British Columbia	N/A

See all ALDOMET clinical trials

US Patents and Regulatory Information for ALDOMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	ALDOMET	methyldopate hydrochloride	INJECTABLE;INJECTION	013401-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	ALDOMET	methyldopa	TABLET;ORAL	013400-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	ALDOMET	methyldopa	SUSPENSION;ORAL	018389-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck	ALDOMET	methyldopa	TABLET;ORAL	013400-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	ALDOMET	methyldopa	TABLET;ORAL	013400-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for ALDOMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	ALDOMET	methyldopa	SUSPENSION;ORAL	018389-001	Approved Prior to Jan 1, 1982

Market Dynamics and Financial Trajectory for Aldomet (Methyldopa)

Last updated: February 27, 2026

What is Aldomet?

Aldomet (generic: methyldopa) is an antihypertensive agent used primarily to treat high blood pressure. It is a centrally acting alpha-2 adrenergic agonist approved by the FDA in 1962. Its patent expired in the 1980s, making generic versions widely available. The drug is mainly prescribed for pregnant women with hypertension due to maternal safety considerations.

Market Overview

Current Market Size

The global antihypertensive drugs market was valued at approximately $33 billion in 2022, with central nervous system (CNS) acting antihypertensives, including methyldopa, comprising a small segment of this figure. Aldomet accounts for less than 1% of the overall market, reflecting limited current demand.

Key Market Drivers

• Fertility and Pregnancy Focus: Methyldopa remains an option for hypertensive pregnant women when other drugs pose risks. This niche sustains a baseline demand.

• Stable Generic Supply: As a generic drug, Aldomet benefits from competitive pricing and large-scale manufacturing capacity, ensuring ongoing availability.

Market Constraints

• Shift to Newer Agents: There is a trend toward prescribing newer, more tolerable antihypertensives such as ACE inhibitors, ARBs, and calcium channel blockers.

• Safety and Side Effects: Methyldopa associations with drug-induced hemolytic anemia, hepatotoxicity, and side effects reduce its overall competitiveness.

Competitor Landscape

Aldomet competes against widely prescribed antihypertensives:

Drug Class	Key Drugs	Market Share (~2022)	Notes
ACE inhibitors	Lisinopril, Enalapril	30%	First-line for many patients
ARBs	Losartan, Valsartan	20%	Tolerability advantages
Calcium channel blockers	Amlodipine	15%	Used in specific populations
Beta-blockers	Metoprolol	10%	Reduced in first-line use
Others (including methyldopa)	Various	<5%	Niche applications, off-market

Geographic Distribution

• United States: Predominantly limited to pregnancy-related hypertension.
• Emerging markets: Use is driven by cost considerations, maintaining some demand.
• Europe: Declining due to preferred use of modern agents.

Financial Trajectory

Revenue Trends

Aldomet sales have declined over the last two decades, consistent with the shift toward newer agents and the small niche market. Estimated annual global sales are approximately $15–20 million, with United States sales accounting for around 40%.

Key Factors Affecting Revenue

• Patent Expiry and Generic Competition: Patent expiry in the 1980s allowed for multiple generic manufacturers, suppressing prices.

• Regulatory and Safety Issues: Monitoring regulatory updates is critical, as safety concerns can lead to market withdrawals or usage restrictions.

• Market Penetration: Limited to specialty settings, primarily maternal health.

Future Revenue Projections

Based on the current market and trends:

Scenario	Est. Market Growth	Timeframe	Projected Annual Revenue
Conservative	0%	2023-2030	$15 million
Moderate growth	2% annually	2023-2030	$17 million
Decline	-1% annually	2023-2030	$13 million

Factors such as increased use in developing markets or formulation innovations could influence growth marginally. However, regulatory pressure for newer agents is unlikely to shift demand significantly.

Regulatory and Patent Landscape

• Patent Status: No patents for methyldopa remain; market is dominated by generics.

• Regulatory Actions: Ongoing safety monitoring by FDA and EMA; no recent major recalls.

Outlook and Opportunities

• Therapeutic niche: Focus on hypertensive pregnant women in regions with limited access to newer drugs.

• Formulation innovations: Extended-release formulations are not commercially prevalent, which could offer marginal differentiation.

• Market expansion in developing nations: Cost-sensitive healthcare systems may sustain some demand.

Key Takeaways

• Aldomet has a minimal market share within the global antihypertensive market.
• The drug's usage is constrained primarily to pregnancy-related hypertension.
• Sales are stable but declining, driven by competition from newer, better-tolerated drugs.
• No patent protections remain; the drug exists solely as a generic.
• Future growth depends on niche applications and regional demand, with limited prospects for significant expansion.

FAQs

What are the primary clinical uses of Aldomet?
Treatment of hypertension in pregnant women where other drugs are contraindicated or less suitable.

Is Aldomet still commercially viable?
Yes, in niche markets, particularly in regions with cost constraints and limited access to newer agents.

Are there developments in Aldomet formulations?
No significant recent innovations, although extended-release versions are not available.

What are the safety concerns associated with Aldomet?
Potential for hemolytic anemia, hepatotoxicity, and other side effects, leading to cautious use.

Could new patents or formulations revive Aldomet’s market?
Unlikely, as patent protections have expired, and safety profile concerns limit innovation incentives.

References

1. GlobalData. (2022). Antihypertensive drugs market report.
2. U.S. Food and Drug Administration (FDA). (2022). Drug approvals and safety alerts.
3. MarketWatch. (2023). Pharmaceuticals: trends and forecasts.
4. European Medicines Agency (EMA). (2023). Regulatory updates on antihypertensive agents.
5. IMS Health. (2022). Global pharmaceutical sales and market share data.